Methotrexate and leflunomide combination therapy for patients with active rheumatoid arthritis

Clinical and Experimental Rheumatology

Volumn 17, Issue 6 SUPPL. 18, 1999, Pages

  Mroczkowski, P J ^a   Weinblatt, M E ^b   Kremer, J M ^a  

^a ALBANY MEDICAL COLLEGE   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Combination therapy; Leflunomide; Methotrexate; Rheumatoid arthritis

Indexed keywords

LEFLUNOMIDE; METHOTREXATE;

ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; HUMAN; LIVER TOXICITY; MULTICENTER STUDY; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; TREATMENT OUTCOME;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DRUG THERAPY, COMBINATION; HUMANS; ISOXAZOLES; METHOTREXATE;

EID: 0032694697     PISSN: 0392856X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. MLADENOVIC V, DOMLJAN Z, ROZMAN B et al.: Safety and effectiveness of leflunomide in the treatment of patients with active rheumatoid arthritis: Results of a randomized, placebo-controlled phase II study. Arthritis Rheum 1995; 38: 1595-603.
2. SMOLEN JS, KALDEN JR, ROZMAN B, et al.: Efficacy and safety of leflunomide compared to placebo and sulphasalazine in active rheumatoid arthritis: A double-blind, randomised, multicentre trial. Lancet 1999; 353: 259-66.
3. WEAVER A, CALDWELL J, OLSEN N, COHEN S, and STRAND V for the Leflunomide RA Investigators Group: Treatment of active rheumatoid arthritis with leflunomide compared to placebo or methotrexate [abstract]. Arthritis Rheum 1998; 9 (Suppl.): S131.
4. DAVIS JP, CAIN GA: The immunosuppressive metabolite of leflunomide is a potent inhibitor of human dihydroorotate dehydrogenase. Biochemistry 1996; 35: 1270-3.
5. CHERWINSKI HM, COHN, RG, CHEUNG P, et al.: The immunosuppressant leflunomide inhibits lymphocyte proliferation by inhibiting pyrimidine biosynthesis. J Pharmacol Exp Ther 1995; 275: 1043-9.
6. CHERWINSKI HM, BYARS N, BALLARON SJ, NAKANO GM, YOUNG JM, RANSOM JT: Leflunomide interferes with pyrimidine nucleotide biosynthesis. Inflamm Res 1995; 44: 317-22.
7. HERRMANN ML, FRANGOU CG, SIMMONDS HA, KIRKSCHBAUM B: The primary mode of action of leflunomide in rheumatoid arthritis is inhibition of de novo pyrimidine synthesis. Arthritis Rheum 1998; 9 (Suppl.): s35.
8. FOX RI: Mechanism of action of leflunomide in rheumatoid arthritis. J Rheumatol 1998; 25: Suppl. 53: s20-6.
9. FOX R, MAHBOUBI A, GREEN D et al.: Leflunomide inhibits de novo uridine synthesis and is dependent on p53 for arrest in G1 phase of cell cycle. Arthritis Rheum 1998; 9 (Suppl.): s137.
10. CRONSTEIN BN: Methotrexate and its mechanism of action. Arthritis Rheum 1996; 39: 1952-60.
11. KREMER JM: Methotrexate and leflunomide: biochemical basis for combination therapy in the treatment of arthritis. Semin Arthritis Rheum 1999; 29: 14-26.
12. WEINBLATT ME, KREMER JM, COBLYN JS et al.: Leflunomide plus methotrexate in refractory rheumatoid arthritis: A pilot study. Arthritis Rheum 1997; 40 (Suppl. 9): s193.
13. WEINBLATT ME, KREMER JM, COBLYN JS et al.: Pharmacokinetics, safety, and efficacy of the combination of methotrexate and leflunomide in patients with active rheumatoid arthritis. Arthritis Rheum 1999; 42: 1322-7.
14. ARNETT FC, EDWORTHY SM, BLOCH DA et al.: The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31: 315-24.
15. KREMER JM, ALARCON GS, LIGHTFOOT RW JR et al.: Methotrexate for rheumatoid arthritis: Suggested guidelines for monitoring liver toxicity. Arthritis Rheum 1994; 37: 316-28.